# US 11,299,518 B2 · Fusion respiratory syncytial virus inhibitors and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,299,518 B2
- Document ID: US11299518B2
- Status: Granted
- Kind: B2
- Application number: 16/081,431
- Filed: 2017-03-02
- Published: 2019-02-21
- Granted: 2022-04-12
- Earliest claimed: 2016-03-03
- Assignees: Fondation the Ark
- Applicants: Fondation the Ark
- Inventors: Origene Nyanguile; Jean-Manuel Segura; Dominique Garcin
- Web page: https://patentgrep.com/patent/US11299518B2

## CPC

- C07K 14/135: Respiratory syncytial virus
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2760/18521: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/18534: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates novel peptides useful for the prevention and/or treatment of respiratory syncytial virus (RSV) infections.

## Claims

### Claim 1

A compound selected from the group consisting of SEQ ID NOs: 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, and 49.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein said compound is SEQ ID NO: 36 or 37.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein said compound is SEQ ID NO: 38 or 39.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein said compound is SEQ ID NO: 40 or 41.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein said compound is SEQ ID NO: 42 or 43.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein said compound is SEQ ID NO: 44 or 45.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein said compound is SEQ ID NO: 46 or 47.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein said compound is SEQ ID NO: 48 or 49.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising at least one compound according to claim 1.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, wherein the composition further comprises at least one agent useful for the treatment of viral infections.

### Claim 11 (depends on 1)

A method for reducing the likelihood of RSV infection or treating a subject suffering from a RSV infection comprising administering at least one compound according to claim 1 or a pharmaceutical formulation thereof to a subject in need thereof.

### Claim 12 (depends on 11)

The method according to claim 11, wherein said RSV infection is lower respiratory infection caused by RSV.

### Claim 13 (depends on 11)

The method according to claim 11, wherein said at least one compound is SEQ ID NO: 46.